Innovative approaches to improve in vivo efficacy

Genetically modified immune cell therapies use cells that have been engineered to improve their abilities to fight cancer, infectious disease, and other applications. Such approaches have been leveraged to produce T cells, B cells, and natural killer cells that express transgenic T cell receptors (TCRs), chimeric antigen receptors (CARs), and other enhancements. In the case of cancer, the goal of this approach is to improve tumor-specific immunogenicity and to enhance tumor cell killing. 

Despite early successes, there are limitations that complicate the development, testing, and manufacturing of TCR-T, CAR-T, and NK cell therapies. These include:

• Lack of standard potency assays to measure biological activity and efficacy 
• Suboptimal tumor cell models and difficulties in solid tumor cell targeting
• Challenges in assessing metabolic status to improve immune cell activities
  
  

This eBook offers important insight into the state of the industry with a focus on the latest tools and technologies designed to address the challenges of immune cell therapy development and testing.